An open label trial of OZ101 as an add-on therapy for the treatment of type 2 diabetes mellitus in patients on sulphonylurea monotherapy.

Trial Profile

An open label trial of OZ101 as an add-on therapy for the treatment of type 2 diabetes mellitus in patients on sulphonylurea monotherapy.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs OZ 101 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors OzStar Therapeutics
  • Most Recent Events

    • 06 Sep 2016 Status changed from recruiting to not yet recruiting.
    • 06 Sep 2016 Planned End Date changed from 31 Dec 2015 to 28 Feb 2017.
    • 06 Sep 2016 Planned initiation date changed from 1 Aug 2015 to 31 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top